You are here:

EB lybrido / lybridos

Different Causal Mechanisms for HSDD: Different Treatments

Based on the assumption that different causal mechanisms are responsible for the same symptoms in HSDD, we started a drug development program for two subgroups of women. In one subgroup of women sexual dysfunction occurs as the result of a relatively insensitive system for sexual cues. In another subgroup of patients the sexual complaints result from maladaptive sexual inhibitory mechanisms.

Lybrido (working title) has been developed for patients with HSDD and a relatively insensitive system for sexual cues.

Lybridos (working title) has been developed for women with HSDD and maladaptive sexual inhibitory mechanisms.

Both drug candidates can be taken ‘on demand’ and help to increase central sexual motivation (libido) about 3 to 6 hours after intake.

Moreover, we have developed an algorithm (simple, practical and useable), partly based on genetics, by which a differentiation can be made between Lybrido and Lybridos responders.